Category: Clinical Trial News
Opportunity: Marketing material for clinical trial data analysis CROs and vendors
Issue: Incorrect clinical trial data
Latest trigger event for Opp: Nektar PR August 7, 2023
Target Companies: Clinical trial data analysis CROs and vendors
Details:
Nektar Therapeutics announced that efficacy data previously analyzed by Eli Lilly and/or its CRO, for rezpegaldesleukin (REZPEG) that were presented at the September 2022 EADV Congress were incorrectly calculated. The erroneous data is from two Phase 1b studies:
• Atopic Dermatitis
• Psoriasis
Upon corrected analysis EASI-related & PASI-related efficacy endpoints were met.
Nektar discovered the EASI-related and PASI-related clinical efficacy endpoints were incorrectly calculated by Lilly after all rights to REZPEG were returned to Nektar. When the raw data files were transferred to Nektar, Nektar employed an independent statistical firm to analyze the raw data de-novo, and the firm provided the new and corrected data. The internal statistical and clinical teams in charge of the two studies at Lilly were made aware and Lilly confirmed the errors in written communications with Nektar.
About Nektar Therapeutics
Company Type: Public Company
Market Cap (8/9/23): $174,800,000
Location: San Francisco, California
Cash (Q1 2023): $456,800,000
Burn rate/quarter: $-66,870,000
Technology Focus: Biologic
Latest stage asset: Phase 3
Indications: Oncology, immunology, and virology
Key employees: Subscribe to learn more!
💡 Do you sell your products or services to biopharma companies? 💡
BiopharmIQ MarketCompass is a market intelligence tool to help with your business development. Get a free sample report of potential targets.
Article History:
Originally posted 8/15/23 (RB)
Comments